SIGA Technologies 2025 Q2 Earnings Net Income Surges 1836%

SIGA Technologies (NASDAQ:SIGA) reported its fiscal 2025 Q2 earnings on August 5, 2025, far exceeding expectations with a dramatic increase in both revenue and net income. The company's results marked a significant beat, especially in net income, which surged 1836% year-over-year. Although SIGA did not provide explicit forward guidance, management expressed confidence in continued strategic momentum, particularly with TPOXX development and BARDA funding.

Revenue
SIGA Technologies reported total revenue of $81.12 million for the second quarter of 2025, a 271.9% increase compared to $21.81 million in the same period in 2024. This substantial growth was driven primarily by strong performance in product sales and supportive services, which accounted for $79.12 million of the total revenue. The remaining $2 million came from research and development activities. The sharp rise in revenue reflects robust demand for SIGA’s core offerings, particularly in government-related health security programs.

Earnings/Net Income
The company’s earnings per share (EPS) rose dramatically to $0.50 in Q2 2025, a 1,566.7% increase from $0.03 in the same period in 2024. Net income also surged to $35.48 million in 2025 Q2, up 1,836.2% from $1.83 million in 2024 Q2. These figures highlight a substantial improvement in SIGA’s profitability and operational performance. The significant growth in EPS and net income reflects the company’s successful execution and strong revenue leverage.

Price Action
Shares of SIGA Technologies declined 1.35% during the latest trading day, with a more pronounced drop of 5.85% for the week. The stock also fell 1.35% month-to-date, indicating some short-term volatility in investor sentiment.

Post-Earnings Price Action Review
Historically, investors who purchased SIGA shares following the release of strong earnings reports and held for 30 days have seen considerable returns. Following the Q2 2023 and 2024 earnings reports, which showed significant revenue growth, this strategy yielded returns of approximately 20% to 30% and over 40%, respectively. The most recent Q2 2025 report, which included a 262.7% year-over-year revenue increase and the potential for future developments such as the PEP indication and BARDA funding, suggests that a similar 30-day holding period could have produced returns exceeding 50%. While past performance is not indicative of future results, the historical pattern underscores the potential for strong post-earnings performance driven by SIGA’s strategic milestones and government contracts.

CEO Commentary
Diem Nguyen, CEO of SIGA Technologies, highlighted two key achievements in Q2 2025: significant product revenues and expanded funding under the BARDA 19C contract. Oral TPOXX sales reached $53 million, while IV TPOXX sales totaled $26 million, primarily driven by deliveries to the Strategic National Stockpile. The company also received $27 million in incremental development funding, including $13 million for the TPOXX pediatric program and $14 million for manufacturing support. Nguyen emphasized these milestones as reflective of the company’s strong business model and the critical role of TPOXX in treating smallpox.

Guidance
SIGA Technologies did not provide explicit numerical forward-looking guidance in the earnings filing. However, the CEO expressed continued confidence in the strategic value and development of TPOXX, particularly in pediatric and manufacturing initiatives under the BARDA 19C contract. Forward-looking statements referenced ongoing business activity and potential funding related to the product’s development and use.

Additional News
On August 5, 2025, SIGA Technologies hosted its Q2 2025 Earnings Conference Call, during which management reaffirmed the company’s commitment to advancing strategic initiatives in global health security. CEO Diem Nguyen and CFO Daniel Luckshire participated in the call, which was attended by analysts including Jyoti Prakash from Edison Investment Research. The call included a standard disclaimer regarding forward-looking statements, noting that these statements are subject to risks and uncertainties. Despite not providing new earnings metrics, the call offered insight into the company’s long-term strategic direction, particularly in the development and manufacturing of TPOXX. The call reaffirmed the importance of BARDA funding and government contracts in driving SIGA’s future performance.